Much of our knowledge of the protein PD-1, a leading cancer treatment target, comes from studies in mice. In a comprehensive assessment of PD-1, researchers have found that PD-1 in mice is ...

Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments. A "checkpoint" receptor that often resides on the surface ...

Programmed cell death protein 1,” or PD-1, has been considered a key target in cancer therapies since its discovery in the ...

Cancer immunotherapy drugs called immune checkpoint inhibitors take the brakes off the body’s immune system, allowing it to ...

Researchers have discovered that mouse PD-1 is significantly weaker than human PD-1, calling into question their reliability ...

This executive interview, sponsored by BeiGene, is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene.

About LM-299 LM-299 is an investigational bispecific antibody targeting both programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF). This innovative therapeutic ...